Full Press Release Details
Technologies: Professor Eddy Fan, Expert in Critical Care Medicine and
Extracorporeal Support, Joined Inspira's
Scientific Advisory Board
Fan currently serves as the medical director of the extracorporeal life
support program at the Toronto General Hospital
Israel, November 30, 2021 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira
Technologies"), a groundbreaking respiratory support technology company, announced today that Professor Eddy Fan, an expert in
critical care and extracorporeal life support methods, has joined Inspira Technologies' Scientific Advisory Board.
Fan is an associate professor in the Interdepartmental Division of Critical Care Medicine and the Institute of Health Policy, Management
and Evaluation at the University of Toronto and a staff intensivist at the University Health Network/Mount Sinai Hospital. Prof. Fan currently
holds the medical director of the extracorporeal life support program at the Toronto General Hospital.
Prof. Eddy Fan, commented: "It is
exciting to work with Inspira Technologies to design and develop novel extracorporeal support
devices that will hopefully provide an additional tool for clinicians treating patients with acute respiratory failure and acute respiratory
distress syndrome (ARDS)."
Fan received an undergraduate degree from the University of Toronto, his medical degree from the University of Western Ontario and a doctorate
in clinical investigation from Johns Hopkins University.
Fan's area of academic focus is acute respiratory distress syndrome (ARDS), mechanical ventilation and extracorporeal support. His research
has focused on advanced life support for acute respiratory failure and patient outcomes after critical illness. These include investigations
of the epidemiology and use of mechanical ventilation and extracorporeal life support in patients with ARDS, as well as on the development
of ICU-acquired weakness, early rehabilitation in ICU patients, and long-term outcomes in survivors of critical illness.
his most significant publications:
Dagi Ben-Noon, Inspira Technologies'
Chief Executive Officer stated: "We are honored to have Professor Fan on Inspira Technologies'
Scientific Advisory Board. Professor Fan is a distinguished researcher, and his scientific expertise will be of great significance to
Inspira Technologies in the development and potential deployment of its ART device."
About Inspira Technologies OXY B.H.N. Ltd.
Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective
early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory
patients. The ART device is designed to utilize a hemo-protective flow approach aimed at rebalancing oxygen saturation levels while patients
are awake and breathing, potentially minimizing the patient's need for mechanical ventilation. The Company's product has not yet
been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA) or the CE or other required regulatory
more information, please visit our corporate website: www.inspirao2.com
Statement Disclaimer
press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company
is using forward-looking statements when it discusses that Prof. Fan will assist in the design and development of develop novel
extracorporeal support devices that will hopefully provide an additional tool for clinicians treating patients with acute respiratory
failure and ARDS and that Prof. Fan's scientific expertise will be of great significance
in the development and potential deployment of its ART device. These forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the
Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties
affecting the Company is contained under the heading "Risk Factors" in the Company's Registration Statement on Form
F-1 filed with the SEC, as well as its subsequent public filings, which are available on the SEC's website, www.sec.gov.
Miri Segal, Investor Relations, MS-IR LLC,
+917-607-8654, msegal@ms-ir.com